Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001210559 | SCV001382053 | uncertain significance | Dilated cardiomyopathy 1JJ | 2024-01-31 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with valine, which is neutral and non-polar, at codon 596 of the LAMA4 protein (p.Glu596Val). This variant is present in population databases (rs781829812, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with LAMA4-related conditions. ClinVar contains an entry for this variant (Variation ID: 940882). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV001210559 | SCV002789473 | uncertain significance | Dilated cardiomyopathy 1JJ | 2021-08-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004639495 | SCV005132374 | uncertain significance | Cardiovascular phenotype | 2024-05-06 | criteria provided, single submitter | clinical testing | The p.E596V variant (also known as c.1787A>T), located in coding exon 13 of the LAMA4 gene, results from an A to T substitution at nucleotide position 1787. The glutamic acid at codon 596 is replaced by valine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |